Clinical Trial Update: ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating ADZENYS XR-ODT in children aged 4 to under 6 with ADHD has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• ADZENYS XR-ODT (amphetamine)

Snippet

Sponsor: Aytu BioPharma, Inc. | Conditions: Attention Deficit Hyperactivity Disorder | Phase 4 | Status: WITHDRAWN